Navigation Links
Nventa Appoints Gordon H. Busenbark to Board of Directors
Date:5/28/2008

- Busenbark Provides Additional Global Corporate Finance, Management and

Manufacturing Experience -

SAN DIEGO, May 28 /PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals Corporation (TSX: NVN) announced today the appointment of Gordon H. Busenbark to the company's board of directors. Mr. Busenbark currently serves as the chief financial officer of Xytis Pharmaceuticals, a privately held development-stage specialty pharmaceuticals company focused on diseases of the central nervous system.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080303/LAM023LOGO)

"With his extensive experience in the pharmaceutical, biotech and vaccine industries, Gordon is a valuable addition to Nventa's board," commented Gregory M. McKee, president and chief executive officer at Nventa. "His 28 years of industry experience include overseeing billion dollar businesses in both the U.S. and Europe. We believe this key global experience, coupled with his proven track record in corporate finance and manufacturing, will serve Nventa well as we continue to advance our lead product candidate through development and toward commercialization."

Prior to joining Xytis in 2007, Mr. Busenbark was the chief financial officer of Encysive Pharmaceuticals, a publicly traded specialty pharmaceuticals company focused on vascular disease. In this role, he was responsible for securing external financing, all aspects of Security and Exchange Commission (SEC) reporting, Sarbanes-Oxley compliance, budgeting, forecasting, strategic planning and investor relations activities. From 1981 through 2004, Mr. Busenbark held various leadership positions with Baxter Healthcare Corporation, including president of Baxter BioScience's plasma therapeutics business in Vienna, Austria. Mr. Busenbark began his career as a senior financial analyst at Burroughs Corporation. He received a bachelo
'/>"/>

SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
2. Nventa announces publication of HspE7 data
3. Nventas CEO to present at two upcoming investor conferences
4. Nventa updates progress of cervical dysplasia trial with new HspE7
5. Nventa Biopharmaceuticals Corporation announces third-quarter 2007 financial results
6. Nventa completes enrollment and initial dosing of second cohort in Phase 1 HspE7 safety trial
7. Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results
8. Nventa Appoints John Varian to Board of Directors
9. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
10. Codexis Appoints Singapore Laboratories Managing Director
11. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... Clinovo Staffing Solutions will ... held in Orlando, FL on May 17-20th, 2015. ... Leslie Kolman, Manager of Staffing Solutions, will present Clinovo’s ... Booth #17. , “We are excited to be ... Says Trisha Heredia, Senior Director of Staffing Solutions at ...
(Date:4/29/2015)... USA (PRWEB) April 29, 2015 ... sensing, and imaging on the East Coast, reaffirmed its ... managers, researchers, applications developers, and industry suppliers to meet ... imaging for multiple applications. , The event included 55 ... commercial and scientific sensing and imaging -- and an ...
(Date:4/29/2015)... 2015 Cambrex Corporation (NYSE: CBM ) announced ... Friday, May 1, 2015 before the market opens. , ... host a conference call to discuss the financial results. First ... , Friday, May 1, 2015 at 8:30 a.m. Eastern ... U.S.1-719-325-2454 for International  Passcode:  7993632 Dial-in Replay: ...
(Date:4/29/2015)... Gene therapy can clip out genetic material linked to ... human cardiac cells, according to a study led by researchers ... at Mount Sinai. The study is published in the April ... small random, changes in the genetic code making up genes, ... patients with heart failure,” says Roger J. Hajjar, MD, Director ...
Breaking Biology Technology:Clinovo Exhibits at the 2015 PharmaSUG Annual Conference on May 17-20th in Orlando, FL 2Clinovo Exhibits at the 2015 PharmaSUG Annual Conference on May 17-20th in Orlando, FL 3SPIE DSS provides venue for collaboration vital to research, applications advances 2SPIE DSS provides venue for collaboration vital to research, applications advances 3SPIE DSS provides venue for collaboration vital to research, applications advances 4Gene Therapy Clips Out Heart Failure Causing Gene Mutations 2Gene Therapy Clips Out Heart Failure Causing Gene Mutations 3Gene Therapy Clips Out Heart Failure Causing Gene Mutations 4
... (Nasdaq:,CEPH) today announced that the U.S. Food and ... Drug Application (sNDA) for,FENTORA(R) (fentanyl buccal tablet) [C-II] ... with chronic pain. In,addition, the FDA notified the ... on May 6, 2008, to consider this application., ...
... AMDL, Inc. (Amex:,ADL), headquartered in Tustin, ... China, through its wholly owned subsidiary Jade,Pharmaceutical ... together,with Jade, engages in the development, manufacture ... diagnostic products. It today,announced that more than ...
... Jan. 25 ImaRx Therapeutics,Inc. (Nasdaq: IMRX ... Administration,(FDA) has approved the company,s most current lot ... first lot to be released with extended,expiration dating. ... thrombolytic or clot-dissolving agent indicated,for the treatment of ...
Cached Biology Technology:Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application 2Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application 3AMDL Signs 100 Strategic Cooperation Agreements in China for Its JPGreen Clinics; Gross Sales Per Each Location Could Exceed $400,000 2ImaRx Therapeutics Receives Urokinase Lot Release Approval With Extended Expiration Dating 2ImaRx Therapeutics Receives Urokinase Lot Release Approval With Extended Expiration Dating 3
(Date:4/13/2015)... 2015  higi, a leading cloud-based consumer engagement platform ... engage with their communities around health and wellness, announced ... secure API.  ... affordable, and convenient vehicle to receive validated health information ... The API will allow higi,s trusted partners, on ...
(Date:4/9/2015)... , April 9, 2015 Synaptics Inc. (NASDAQ: ... announced today that it will report financial results for ... 23, 2015, after the close of market. The company ... investors at 2:00 p.m. PT (5:00 p.m. ET), during ... To participate on the live call, analysts and investors ...
(Date:4/6/2015)... Conn. , Apr. 6, 2015 NXT-ID, ... "Company"), a biometric authentication company focused on the ... has filed provisional patent 62/143028 for ... COMMUNICATIONS AND ENERGY TRANSFER  NXT-ID introduces a ... payments. This patent surrounds the use of miniature ...
Breaking Biology News(10 mins):higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3Synaptics to Report Third Quarter Results on April 23 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4
... Mass. Researchers at the University of Massachusetts Medical School ... is implicated in 20 percent of inherited cases of amyotrophic ... part in sporadic forms of the disease. Discovery of this ... of Nature Neuroscience . While the SOD1 gene ...
... American Academy of Ophthalmology (AAO) - Middle East-Africa ... report on beta carotene,s ability to improve ... The AAO-MEACO meetingthe world,s largest, most comprehensive ophthalmic ... at McCormick Place, Chicago. 9-cis Beta-Carotene Mat ...
... often compared to a book. However, it is not so much ... like a cookbook. The cell reads only those recipes which are ... ,reading, in the book of the cell means creating RNA copies ... The cell uses highly complex, sophisticated regulatory mechanisms to make ...
Cached Biology News:UMMS researchers identify protein associated with sporadic ALS 2UMMS researchers identify protein associated with sporadic ALS 3A mystery solved: How genes are selectively silenced 2
Ezrin/Radixin/Moesin Antibody...
Ezrin/Radixin/Moesin Antibody...
ABCA1 Immunogen: Mouse ABCA1-expressing HeLa stable transfectants. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Goat polyclonal to SART3 ( Abpromise for all tested applications). Antigen: Synthetic peptide: MSNADFAKLFLRK, corresponding to C terminal amino acids 951-963 of Human SART3 Entrez Gene ID: 9...
Biology Products: